Keyword results: LPLDL

Cenkos Securities – Optibiotix shares to more than treble from 45p offer price

It is house broker so it is paid to be bullish and so feel free to ignore everything that follows. None the less, as a loyal shareholder myself, I agree with the valuation in a note out yesterday from Cenkos on Optibiotix (OPTI) commenting on its latest news. The note reads:

PREMIUM CONTENT

OptiBiotix Health and SkinBioTherapeutics – further progress & triggers for dramatic 2022 re-rate

OptiBiotix Health (OPTI) was one of our tips of the year, with we anticipating financial progress as its deals for its compounds expand and further deals kick-in. It has now announced that a further human volunteer study on its cholesterol-reducing probiotic LPLDL - on a different population group of hypercholesterolemic adults – has shown “at six weeks, when volunteers taking placebo were compared to those taking LPLDL, there were statistically significant changes to clinically important cardiovascular risk”, including “34.2% reduction in total cholesterol (p=0.001)”.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – extends Seed Health territories, strong buy

OptiBiotix Health (OPTI) has announced further growth with an agreement to extend the territories of its deal with Seed Health.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – shares up on ‘trading and commercial update’, much further to go

OptiBiotix Health (OPTI) has made a “Trading and commercial update” including that sales are ahead of its expectations for the first six months of the year and that it “believes it is in a strong position to meet or exceed its full year sales forecast”. The shares have currently responded up to 49.5p but there looks much further to go.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – strong commercial progress & company chat: this will be inflexion year: buy

OptiBiotix Health (OPTI) has announced a “Commercial strategy update” which shows strong progress in its strategy to initially build sales and brand presence and then move up the value chain by selling more product than ingredients and commercialising further compounds. We’ve also had a catch up chat with CEO Steve O’Hara. This should be THE YEAR when profits come close to or exceed £1 million.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – another North American market step & chat with Steve O'Hara - Buy

OptiBiotix Health (OPTI) has emphasised “another step in building brand and product presence in the large North American market” as it announced its latest deal. Yes it is a step but frustratingly one revealed on a release using the Adam Reynolds keyboard. The one with no numbers on it.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – potential extended opportunity into new drug and application areas, strong buy

OptiBiotix Health (OPTI) is “pleased to see that Seed has achieved FDA authorisation for an IND in a product containing OptiBiotix’s Lactobacillus plantarum LPLDL®”. So, what does this mean?…

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – LPLDL & CholBiome distributor agreement, strong buy...

OptiBiotix Health (OPTI) is “pleased to announce… an exclusive distribution agreement with Ayalla Marketing for the distribution of its cholesterol reducing probiotic, LPLDL®, as an ingredient and as four finished products (CholBiome, CholBiomeX3, CholBiomeBP and CholBiomeVH) within the CholBiome® portfolio for Brazil”

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – clarifications and updates on more news from the company

More news from OptiBiotix Health (OPTI) and we’re also asked to clarify re. previous statements by the company...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – shares down on historic numbers but look at the trading trajectory now...

Currently compounds to tackle obesity, high cholesterol and diabetes developer, OptiBiotix Health (OPTI) has announced results for the 13 months to 31st December 2019 (having moved its year-end from November), emphasising it “has met a significant number of important objectives that continue to build value for shareholders”. The shares have currently responded a bit lower to 62p, but the numbers are historic and look at the trading trajectory now...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – sales trajectory sparks shares, but still an even stronger buy...

OptiBiotix Health (OPTI) has updated including noting first quarter of 2020 sales of £407,844 – and the shares have responded 11% higher to above 60p. Capitalising the company at around £53 million, why you may ask? Well, look at the company’s trajectory...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – modified and extended agreement RNS emphasises attractiveness & share price fall

I have communicated with Steve O Hara. The share price of Optibiotix (OPTI) is 34p and that is freaking some folks out. The share price does not reflect what is going on. I think a formal trading statement would be useful.

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix – LPLDL South America RNS & breaking news from H&B UK, Strong Buy

OptiBiotix Health (OPTI) has announced “a significant milestone” in extension of the use of its LPLDL probiotic strain into functional foods and its presence into South America. So what you say?...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – validations look to significantly increase LPLDL potential, remains a strong buy

OptiBiotix Health (OPTI) has updated investors with news including “completing Pharmaceutical GMP process validation and receiving the GRAS notification letter from the US FDA is a significant achievement for ProBiotix and LPLDL®. Few marketed probiotics have achieved this level of proven safety and efficacy and it has triggered another milestone payment in the US Pharmaceutical agreement”

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – positive scientific and commercial update

An update from OptiBiotix Health (OPTI); “Scientific and commercial update”...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

OptiBiotix Health – license agreement momentum continues

More positive news from OptiBiotix Health (OPTI)?... The company has announced an exclusive license agreement for the commercialisation of, currently fully-owned subsidiary, ProBiotix's cholesterol management products CholBiome and CholBiomex3 in Vietnam…

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Optibiotix – another week, another deal

Last week it was a Thai deal from OptiBiotix Health (OPTI), now there’s another for the European market...

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Optibiotix – another day another deal, but a question...

Steve O’ Hara says he is looking to do two new distribution deals a month and so here is the first for May. Optibiotix (OPTI) has announced that its fully-owned subsidiary ProBiotix Health Ltd., has signed a license agreement with Instituto Español de Nutrición Personalizada, S.A. for the use of Lactobacillus plantarum (LPLDL) in personalised food supplements in Spain...

Subscribe to ShareProphets to access Premium Content

Optibiotix – another step forward, deal with HLH extended, BUY

Another day and another small piece of what will be an enormous jigsaw falls into place.

PREMIUM CONTENT

Optibiotix – and now a big deal in Japan: shares to hit 125p by Easter + CEO Video

Another day and another hugely positive announcement from Optibiotix (OPTI) to delight we loyal shareholders.  This news is from Japan.

Subscribe to ShareProphets to access Premium Content

Optibiotix – another day another deal: many more to come (soon!)

The latest deal from Optibiotix (OPTI) is a three year distribution agreement with a company called SilvEXPO Ltd to distribute and commercialise OptiBiotix's own label CholBiome products containing its cholesterol and blood pressure reducing LPLDL strain in Russia and Kazakhstan...

PREMIUM CONTENT

OptiBiotix Health - again a buy

Having reached circa 130p in August, shares in OptiBiotix Health (OPTI) have slid to 78p-81p. This is despite a pipeline of seemingly very significant deals likely to be converted and as such…

Subscribe to ShareProphets to access Premium Content
PREMIUM CONTENT

Optibiotix – Big Italian deal but Nomad needs shooting – shares are a strong buy

Optibiotix (OPTI) has announced what is its 14th (or is it 15th) big commercial partnership. But how big? Thanks to a Nomad who needs shooting it has taken us 36 hours to find out. So here goes.

Subscribe to ShareProphets to access Premium Content

Optibiotix - biggest deal yet, Mr Market does not realise - STRONG BUY

This may well be the biggest supply deal yet announced by Optibiotix (OPTI) but Mr Market seems unmoved. The shares are 73p-75p and are a STRONG BUY. Let us explain.

Optibiotix - show launch & video up, STRONG BUY

It is not exactly earth shattering but Optibiotix (OPTI) says that it will be showcasing "an extended range of products and presenting new research data on its LPLDL® and SlimBiome® products at the Vitafoods European tradeshow in Geneva from the 15-17 May 2018."

BONUS REPORT: Optibiotix - why the shares (now 73p offer) will head past 100p by Christmas

Okay we have been bullish on this one since the shares were 8p – when we bought our shares –  but it has not raced ahead in recent months as much as we would have expected. The market simply has not appreciated the importance of recently announced deals and also the business model. Once it does, and that will come as other big deals are announced, the shares will move ahead very sharply indeed.

Optibiotix - Research Paper News. It's dry but the stance is Buy

This is not going to get the shares soaring, but it is further affirmation of the technology that Optibiotix (OPTI) owns and which it is showing an increasing ability to monitise.

OptiBiotix – new supply agreement… and more to come

A previous announcement from OptiBiotix (OPTI) we lambasted as non-news, but noted we expected a rally from the then 65p-66.5p on real news for which we will not be waiting long. The company is today “pleased to announce” a three year supply agreement with Spain-headquartered pharmaceutical group Galenicum “to commercialise products containing OptiBiotix's cholesterol and blood pressure reducing strain, LPLDL.

Optibiotix - launch of Slimbiome and LPLDL products. Read closely & buy

OptiBiotix Health (OPTI) has announced what it terms the "successful" launch of its SlimBiome® and LPLDL® products at the Vitafoods Europe tradeshow in Geneva from the 9-11 of May 2017. The event provided the opportunity to connect with 16,500 industry decision makers from the supplements, nutraceutical, functional food and beverage industries. This is viewed as one of the world's leading trade fairs for the food and drinks industry. Yadda, yadda, yadda. Companies always say launches are successful. More jam tomorrow. So what. Etc. But no read on... We have underlined a few key words for you.

Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments

|